Skip to content

The effect of omega3 supplementation on plasma Peroxisome proliferator-activated receptors( ppar?) in obesity

The effect of omega3 supplementation on plasma Peroxisome proliferator-activated receptors( ppar?) in obesity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903162017N3
Enrollment
60
Registered
2011-04-30
Start date
2011-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: 2 omega3 capsula with 1 gr weight(containing 360 mg EPA and 240 mg DHA). Intervention 2: Pacebo group: 2 placebo capsula (containing paraffin).
Treatment - Drugs
Intervention group: 2 omega3 capsula with 1 gr weight(containing 360 mg EPA and 240 mg DHA)
Pacebo group: 2 placebo capsula (containing paraffin)

Sponsors

Nutritional research center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: BMI>30, and age 18-45 yrs. Exclusion criteria: Pregnancy and lactation, menopause, medical history of diabetes mellitus, liver, kidney and thyroid disorders. HIV disease. Any interfering medication with lipid profile. Receiving beta blocker medications. Omega3 or vitamin A supplementation, weight lowering drugs or special diet in the past 2 months and smoking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Plasma PPARgamma. Timepoint: Baseline and at the end of intervention. Method of measurement: ELISA.

Secondary

MeasureTime frame
Thyroid hormons. Timepoint: Baseline and at the end of intervention. Method of measurement: ELISA.;Body composition. Timepoint: Baseline and at the end of intervention. Method of measurement: Bioelectrical Impedance.;Food habits. Timepoint: Baseline and at the end of intervention. Method of measurement: Food Frequency Questionnaire.;Appetite level. Timepoint: Baseline and at the end of intervention. Method of measurement: Visual analog scale questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParizad Taraghijoo

Tabriz University of Medical Sciences

ostadrahimi@tbzmed.ac.ir ; parya_taragi64@yahoo.com+98 914 346 4341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026